Richard Andrews, MD
Neurology with Special Qualifications in Child Neurology · Omaha, NENPI 1659425288
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 488 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 42 manufacturers, the largest accounting for just 16.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,812, 2.3 times the $776 reported in 2019.
Across 488 payments — averaging $18.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Harmony Biosciences LLC$1K
- UCB, Inc.$1K
- SK Life Science, Inc.$738
- Eisai Inc.$567
- AbbVie$548
- Lilly USA, LLC$480
- plus $4K from 36 others
What the payments were for
- Food & beverage$9,02299%
- Education$1301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XCOPRI$250
- Auvelity$240
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$128
- Wakix$125
- LUMRYZ$124
- Symbravo$120
- Austedo XR$120
- Cenobamate$120
- AIMOVIG$106
How this compares
Too few neurology with special qualifications in child neurology providers in Nebraskato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XywavSodium,calcium,mag,pot Oxybate | 12 | $244,190 |
| WakixPitolisant Hcl | 11 | $171,230 |
| Vigabatrin | 13 | $169,186 |
| Rufinamide | 144 | $162,117 |
| XcopriCenobamate | 82 | $143,131 |
| BanzelRufinamide | 19 | $91,136 |
| TopamaxTopiramate | 38 | $79,315 |
| LamictalLamotrigine | 58 | $61,453 |
| KeppraLevetiracetam | 21 | $54,047 |
| Felbamate | 132 | $32,894 |
| ZonegranZonisamide | 14 | $32,575 |
| NayzilamMidazolam | 27 | $29,572 |
| Tiagabine Hcl | 63 | $29,258 |
| Lacosamide | 138 | $26,884 |
| FycompaPerampanel | 25 | $22,169 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Harmony Biosciences LLCWakix | $1,490 | $171,23011 claims |
| SK Life Science, Inc.Xcopri | $738 | $143,13182 claims |
| Eisai Inc.Banzel, Fycompa, Dayvigo | $567 | $127,45584 claims |
| UCB, Inc.Nayzilam, Briviact, Vimpat | $1,472 | $61,87354 claims |
| PfizerEliquis | $140 | $17,21217 claims |
| MerckBelsomra | $46 | $5,43812 claims |
| AbbVieViibryd | $548 | $4,09913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neurology with special qualifications in child neurology providers in Nebraskaon file to place this against a meaningful peer group, so we don't.
Other neurology with special qualifications in child neurology in Omaha
- Geetanjali RathoreOmaha$15K
- Mohaned OsmanOmaha$4K
- Matias Lopez ChaconOmaha$2K
- Samantha ParkhurstOmaha$582
- Rhonda WrightOmaha$415
- Valeria Naranjo IbarraOmaha$309
- Young OliverOmaha$253
- Ahmed AwadOmaha$207
- Janice McAllisterOmaha$175
- Fred KaderOmaha$147
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.